Dulaglutide
- Generic Name
- Dulaglutide
- Brand Names
- Trulicity
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 923950-08-7
- Unique Ingredient Identifier
- WTT295HSY5
- Background
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was appro...
- Indication
Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular r...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 424
- Registration Number
- NCT02597049
- Locations
- 🇵🇷
Manati Medical Center, Manati, Puerto Rico
🇺🇸Grand Street Medical PC, Brooklyn, New York, United States
🇺🇸PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT02152371
- Locations
- 🇺🇸
Valley Endocrine, Fresno, Fresno, California, United States
🇺🇸Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States
🇺🇸Mills-Peninsula Diabetes Research Insitute, San Mateo, California, United States
Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
- Conditions
- Interventions
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT01769378
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Somerset West, South Africa
A Study of Dulaglutide in Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 58
- Registration Number
- NCT01667900
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China
A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 774
- Registration Number
- NCT01648582
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sankt-Petersburg, Russian Federation
A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 737
- Registration Number
- NCT01644500
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yong Kung City, Taiwan
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
- Conditions
- Interventions
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 577
- Registration Number
- NCT01621178
- Locations
- 🇺🇸
Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸Extended Arm Physician, Inc., Montgomery, Alabama, United States
🇺🇸Infosphere, West Hills, California, United States
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
- Conditions
- Interventions
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9901
- Registration Number
- NCT01394952
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Londonderry, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.